GARS1 (Glycyl-tRNA Synthetase 1) is a human gene encoding an essential aminoacyl-tRNA synthetase (ARS) enzyme required for protein synthesis. This enzyme catalyzes the ATP-dependent attachment of glycine to its cognate tRNA (tRNAGly), a critical step in translational accuracy and efficiency. Beyond its canonical role in translation, GARS1 has been implicated in various extra-translational functions including RNA processing, cell signaling pathways, and immune regulation. Dominant mutations in GARS1 cause Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V), making it a key gene in understanding peripheral neuropathy and motor neuron degeneration.
| Gene Symbol | GARS1 |
|---|---|
| Full Name | Glycyl-tRNA Synthetase 1 |
| Chromosomal Location | 7p14.3 |
| NCBI Gene ID | [4197](https://www.ncbi.nlm.nih.gov/gene/4197) |
| OMIM | [600299](https://www.omim.org/entry/600299) |
| Ensembl ID | [ENSG00000106105](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106105) |
| UniProt | [P41250](https://www.uniprot.org/uniprotkb/P41250/entry) |
| Associated Diseases | Charcot-Marie-Tooth disease type 2D (CMT2D), distal spinal muscular atrophy type V (dSMA-V) |
GARS1 encodes glycyl-tRNA synthetase 1, an essential housekeeping enzyme that charges glycine to tRNA during protein synthesis. Dominant gain-of-function mutations cause CMT2D and dSMA-V, characterized by peripheral nerve degeneration affecting motor and sensory neurons. The pathogenic mechanism involves toxic gain-of-function that damages peripheral neurons independent of wild-type GARS levels, with recent research highlighting the role of SIRT2-mediated pathways in GARS-induced neuropathy.
GARS1 belongs to the class II aminoacyl-tRNA synthetase family, which catalyzes the ATP-dependent aminoacylation of tRNA molecules. The enzymatic reaction proceeds through a two-step mechanism:
This aminoacylation reaction is essential for accurate translation of genetic code into protein sequences. GARS1 recognizes both the anticodon loop of tRNAGly (anticodons CCC, CCU, and GCC) and the acceptor stem, ensuring specificity for glycine transfer RNA.
The GARS1 protein contains several key structural domains:
GARS1 functions as a homodimer, with dimerization required for full enzymatic activity. The dimer interface facilitates cooperative tRNA binding and ensures high-fidelity aminoacylation.
Beyond protein synthesis, GARS1 participates in several non-canonical functions:
CMT2D is an axonal form of Charcot-Marie-Tooth neuropathy characterized by:
CMT2D follows autosomal dominant inheritance. GARS1 mutations cause approximately 1-2% of all CMT cases, with over 30 pathogenic variants identified. Common mutations include:
dSMA-V (also known as spinal muscular atrophy, lower extremity-predominant, autosomal dominant) presents with:
Some GARS1 mutations cause intermediate forms of CMT with both demyelinating and axonal features. These variants typically show:
The toxic gain-of-function hypothesis is the leading mechanism for GARS1-associated neuropathy:
Research by Sivakumar et al. (2019) demonstrated that SIRT2 knockdown rescues GARS-induced peripheral neuropathy in mouse models, highlighting SIRT2 as a potential therapeutic target.
GARS1 is ubiquitously expressed across all tissues, reflecting its essential role in protein synthesis. High expression is observed in:
During development, GARS1 expression is highest in embryonic tissues, particularly neural tube and developing limbs. Postnatally, expression remains high in metabolically active tissues requiring continuous protein synthesis.
Gars1C201R/+ knock-in mice: Express CMT2D-causing mutation, develop peripheral neuropathy characterized by:
Gars1Nm2379 mutant mice: Spontaneous ENU-induced mutation causing peripheral neuropathy, useful for studying GARS1 pathomechanisms.
Zebrafish embryos with GARS1 knockdown show:
Drosophila GARS homolog (Aars2) mutants exhibit:
GARS1 interacts with several proteins relevant to neurodegeneration:
| Partner | Interaction Type | Functional Relevance |
|---|---|---|
| AARS2 | Heterodimer | Mitochondrial glycyl-tRNA synthetase |
| YARS1 | Ortholog | Tyrosyl-tRNA synthetase |
| EEF1A1 | Binding | Translation elongation factor |
| RPN2 | Binding | ER-associated degradation |
| SIRT2 | Pathogenic | Deacetylase in axon degeneration |
| VCP | Binding | AAA ATPase in protein quality control |